Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

Semaglutide: Weight loss drug like Ozempic and Wegovy are going to go generic in countries. This means the drug, but in cheaper rates, will be available to the 40 per cent of the world's population.

Novo Nordisk that until now had the monopoly over the drug will lose patent protection in several of the world's most populous countries. Health and Me had also previously reported that the first generic version is expected to arrive in India by this weekend. Soon after, generic drugs will also become available in China, Canada, Brazil, Turkey, and South Africa.

“The availability of these drugs, which have been restricted to high-income countries to very wealthy people, will now be democratized by the generics,” said Leena Menghaney, an activist in New Delhi focused on treatment access. The new markets will open up a huge customer base for the generic weight loss drugs. In India and China, there are more than 800 million obese adults or overweight, and more than 300 million adults have diabetes.

Drugs Could Be Cheaper By 90%

The generic drugs are expected to hit the shelves of Indian markets by 21 March, and costs are expected to be lower by 90 per cent. Drug makers like Nacto Pharma and Eris Lifesciences announced to roll out the weight loss jabs over 50 per cent cheaper than the innovator's price in April. They have also introduced vials for Rs 1,300 per month, which is about 90 per cent cheaper than Ozempic.

Dr Reddy's Laboratories is also gearing up to launch its generic semglutide injection in the country in March under the brand name Obeda. Other companies like Sun Pharma and Zydus Lifesciences too are entering the rat race of launching multiple generic versions to make the treatment more affordable for patients with obesity and weight-related health risks.

Until the patent is expired, the semaglutide therapies are owned by the original company. In India, semaglutide injections like Ozempic and Wegovy are soled at a high cost that has limited accessibility to many patients.

Industry analysts, as reported by NDTV, expect that one generic semaglutide enters the market from March 21, 2026, prices could be cut roughly by 50 per cent as compared to the prices it started with. This means Wegovy which was previously sold for around Rs. 10,000 per month could fall somewhere between Rs 3,500 to Rs. 4,000 per month for starter doses.

Dr Reddy's Laboratories have positioned their generic brands competitively, and could potentially offer discounts of up to 50 to 60 per cent in early competition.

How Does Semaglutide Work?

Semaglutide works as a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and blood sugar. It slows gastric emptying and makes you feel fuller longer. It also signals the brain to reduce hunger and cravings, and triggers the pancreas to release insulin when blood sugar is high.

They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

With the patent on semaglutide expiring today in India, NATCO Pharma has become the first drugmaker to launch the generic version of the weight-loss drug in the country.

NATCO Pharma’s generic semaglutide injection prices start at INR 1,290 per month.

“NATCO is the first company to offer generic semaglutide in multi-dose vials with customized syringes… It is the most affordable GLP-1 currently in the Indian market as it is approximately 70 percent cheaper in cost than the pen device and 90 percent cheaper than the price of the innovator’s brand,” the Hyderabad-based company said, in a statement.

The company had received approval from the Central Drugs Standard Control Organization (CDSCO) in February 2026 to manufacture and market the drug, after a clinical comparison study.

Semaglutide works by targeting key areas of the brain involved in appetite regulation and food intake. It reduces hunger, improves satiety, and cuts down food cravings, eventually inducing weight loss.

It also improves insulin resistance and has a beneficial effect on the reduction of cardiometabolic events and risk factors.

NATCO's Semaglutide Drugs

NATCO's semaglutide drugs will be sold under brand names SEMANAT and SEMAFULL in multi-dose vial formats. It will be priced:

• INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants,
• INR 1,750 for the 8 mg/3 ml dose.

• INR 4,000 for 2 mg/1.5ml,
• INR 4,200 for 4 mg/3 ml,
• INR 4,500 per month for 8 mg/3 ml.

In comparison, Novo Nordisk's Ozempic and Wegovy in pen devices cost INR 8,800 and INR 10,850, respectively, per month for the starting doses.

NATCO has also signed a distribution partnership with Eris Lifesciences to co-market its therapy in India.

Other Generic Versions

Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences are also expected to introduce their versions of semaglutide on Saturday.

Others in the pipeline include Alkem Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

With intense competition, analysts believe around 50 branded semaglutide generics will enter the Indian market within months, BBC reported.

Calling it a potential "magic-pill moment" for India, investment bank Jefferies predicted that the semaglutide market in the country could reach $1bn domestically.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

End Of Novo Nordisk’s Patents

In January this year, Canada became the first country to lose patent protection for semaglutide. However, the country's health regulator hasn’t approved any generics so far.

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

In view of losing patent, Novo Nordisk recently cut prices for Wegovy in India. The company also launched its blockbuster brand Ozempic in December.

Once affecting people who smoked tobacco, lung cancer in India is today more common among people who never smoked. The major reason: exposure to poor air, almost year-round.

Although air pollution has emerged as an important risk for lung cancer, the evidence on this issue from India is limited. To explore more on this, the All India Institute of Medical Sciences, Delhi, today announced undertaking a major study.

The study, dubbed ‘AIRCARE (Air Pollution and Cancer Research Ecosystem): Center for Advanced Research on Environmental Health and Lung Cancer Risk’, will examine the connection between the fine particulate matter 2.5 (PM 2.5) and the risk of lung cancer in the country.

PM2.5 particles, with a diameter of 2.5 micrometers or less, are approximately 30 times smaller than a human hair. It is a significant yet often unseen threat to air quality.

“India is home to some of the most polluted cities in the world, and there is an urgent need to scientifically look at the effects of pollution on people’s health. Lung cancer is one of the most common cancers among males in India, and there is a high number of non-smoking lung cancers among females and young adults,” said Dr. Abhishek Shankar, Assistant Professor, Radiation Oncology at AIIMS, who will lead the study, while addressing the media.

“It is deeply concerning that lung cancer, once assumed to be a disease mostly associated with people who smoke tobacco, is now seeing a rapid increase in incidence amongst people who do not smoke,” he added.

The expert urged the "need to implement policy and management strategies to tackle this disease and mitigate further loss of life”.

The AIRCARE Study

It will be the first-of-its-kind scientific study in India to evaluate the effects of exposure to air pollution.

About 1,615 lung cancer cases with 1,615 controls from their family members will be added to the study.

The study will employ both a cohort and case-control design to track the effects of chronic PM 2.5 exposure on lung cancer incidence across various demographics and socio-economic groups.

It will also attempt to isolate an Indian population-specific genetic imprint.

Based on the findings, the researchers aim to develop a risk- based screening model that will include both clinical and molecular components specific to the Indian population and exposure levels.

It will also identify the susceptible population among the cohort who are more at risk of developing lung cancer.

Lung Cancer And Air Pollution Risks In India

Data from the National Cancer Registry shows that lung cancer affects about 72,000 people and claims 66,000 lives every year in India -- making it one of the leading causes of cancer mortality in the country.

From a smoker’s illness, lung cancer has now emerged as a major concern due to poor air quality. Several doctors across Delhi and Maharashtra have n noted a significant increase in pulmonary cancer due to air pollution.

A 2025 study at a government hospital in North India found that 52 percent of lung cancer cases were among non-smokers.